Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Detection and Characterization of Circulating Tumor Cells in Patients with Merkel Cell Carcinoma.

Riethdorf S, Hildebrandt L, Heinzerling L, Heitzer E, Fischer N, Bergmann S, Mauermann O, Waldispühl-Geigl J, Coith C, Schön G, Peine S, Schuler G, Speicher MR, Moll I, Pantel K.

Clin Chem. 2019 Jan 9. pii: clinchem.2018.297028. doi: 10.1373/clinchem.2018.297028. [Epub ahead of print]

PMID:
30626636
2.

Strengthened scientific support for the Endangerment Finding for atmospheric greenhouse gases.

Duffy PB, Field CB, Diffenbaugh NS, Doney SC, Dutton Z, Goodman S, Heinzerling L, Hsiang S, Lobell DB, Mickley LJ, Myers S, Natali SM, Parmesan C, Tierney S, Williams AP.

Science. 2018 Dec 13. pii: eaat5982. doi: 10.1126/science.aat5982. [Epub ahead of print] Review.

PMID:
30545843
3.

c-Rel is a cell cycle modulator in human melanoma cells.

Priebe MK, Dewert N, Amschler K, Erpenbeck L, Heinzerling L, Schön MP, Seitz CS, Lorenz VN.

Exp Dermatol. 2018 Nov 22. doi: 10.1111/exd.13848. [Epub ahead of print]

PMID:
30466153
4.

Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors.

Moreira A, Loquai C, Pföhler C, Kähler KC, Knauss S, Heppt MV, Gutzmer R, Dimitriou F, Meier F, Mitzel-Rink H, Schuler G, Terheyden P, Thoms KM, Türk M, Dummer R, Zimmer L, Schröder R, Heinzerling L.

Eur J Cancer. 2019 Jan;106:12-23. doi: 10.1016/j.ejca.2018.09.033. Epub 2018 Nov 17.

PMID:
30453170
5.

Centrosomal protein TRIM43 restricts herpesvirus infection by regulating nuclear lamina integrity.

Full F, van Gent M, Sparrer KMJ, Chiang C, Zurenski MA, Scherer M, Brockmeyer NH, Heinzerling L, Stürzl M, Korn K, Stamminger T, Ensser A, Gack MU.

Nat Microbiol. 2019 Jan;4(1):164-176. doi: 10.1038/s41564-018-0285-5. Epub 2018 Nov 12.

PMID:
30420784
6.

Senescence markers: Predictive for response to checkpoint inhibitors.

Moreira A, Gross S, Kirchberger MC, Erdmann M, Schuler G, Heinzerling L.

Int J Cancer. 2019 Mar 1;144(5):1147-1150. doi: 10.1002/ijc.31763. Epub 2018 Dec 4.

PMID:
30151962
7.

Fear of cancer progression in patients with stage IA malignant melanoma.

Wagner T, Augustin M, Blome C, Forschner A, Garbe C, Gutzmer R, Hauschild A, Heinzerling L, Livingstone E, Loquai C, Schadendorf D, Terheyden P, Mueller-Brenne T, Kähler KC.

Eur J Cancer Care (Engl). 2018 Sep;27(5):e12901. doi: 10.1111/ecc.12901. Epub 2018 Aug 20.

PMID:
30126009
8.

[Neurological side effects of checkpoint inhibitors].

Knauss S, Ginesta Roque L, Hühnchen P, Heinzerling L, Böhmerle W, Endres M.

Nervenarzt. 2018 Aug 2. doi: 10.1007/s00115-018-0571-8. [Epub ahead of print] Review. German.

PMID:
30073487
9.

Real world experience in low-dose ipilimumab in combination with PD-1 blockade in advanced melanoma patients.

Kirchberger MC, Moreira A, Erdmann M, Schuler G, Heinzerling L.

Oncotarget. 2018 Jun 22;9(48):28903-28909. doi: 10.18632/oncotarget.25627. eCollection 2018 Jun 22.

10.

The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy: a survey in German melanoma patients and their treating physicians.

Kähler KC, Blome C, Forschner A, Gutzmer R, Hauschild A, Heinzerling L, Livingstone E, Loquai C, Müller-Brenne T, Schadendorf D, Utikal J, Wagner T, Augustin M.

Oncotarget. 2018 May 25;9(40):26217-26225. doi: 10.18632/oncotarget.25439. eCollection 2018 May 25.

11.

MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.

Kirchberger MC, Ugurel S, Mangana J, Heppt MV, Eigentler TK, Berking C, Schadendorf D, Schuler G, Dummer R, Heinzerling L.

Eur J Cancer. 2018 Jul;98:10-16. doi: 10.1016/j.ejca.2018.04.010. Epub 2018 May 26.

PMID:
29843107
12.

Willingness to pay for a cure of low-risk melanoma patients in Germany.

Augustin M, Blome C, Forschner A, Gutzmer R, Hauschild A, Heinzerling L, Livingstone E, Loquai C, Schadendorf D, Utikal J, Wagner T, Wilden S, Kähler KC.

PLoS One. 2018 May 24;13(5):e0197780. doi: 10.1371/journal.pone.0197780. eCollection 2018.

13.

Effective anti-programmed death-1 therapy in a SUFU-mutated patient with Gorlin-Goltz syndrome.

Moreira A, Kirchberger MC, Toussaint F, Erdmann M, Schuler G, Heinzerling L.

Br J Dermatol. 2018 Sep;179(3):747-749. doi: 10.1111/bjd.16607. Epub 2018 Jun 26.

PMID:
29603722
14.

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.

Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, Sullivan RJ, Damrongwatanasuk R, Chen CL, Gupta D, Kirchberger MC, Awadalla M, Hassan MZO, Moslehi JJ, Shah SP, Ganatra S, Thavendiranathan P, Lawrence DP, Groarke JD, Neilan TG.

J Am Coll Cardiol. 2018 Apr 24;71(16):1755-1764. doi: 10.1016/j.jacc.2018.02.037. Epub 2018 Mar 19.

15.

BRAF Inhibitors and Radiation Do Not Act Synergistically to Inhibit WT and V600E BRAF Human Melanoma.

Walter L, Heinzerling L.

Anticancer Res. 2018 Mar;38(3):1335-1341.

PMID:
29491057
16.

Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders.

Kähler KC, Eigentler TK, Gesierich A, Heinzerling L, Loquai C, Meier F, Meiss F, Pföhler C, Schlaak M, Terheyden P, Thoms KM, Ziemer M, Zimmer L, Gutzmer R; German Dermatologic Cooperative Oncology Group (DeCOG).

Cancer Immunol Immunother. 2018 May;67(5):825-834. doi: 10.1007/s00262-018-2134-z. Epub 2018 Feb 27.

PMID:
29487980
17.

Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients.

Hecht M, Meier F, Zimmer L, Polat B, Loquai C, Weishaupt C, Forschner A, Gutzmer R, Utikal JS, Goldinger SM, Geier M, Hassel JC, Balermpas P, Kiecker F, Rauschenberg R, Dietrich U, Clemens P, Berking C, Grabenbauer G, Schadendorf D, Grabbe S, Schuler G, Fietkau R, Distel LV, Heinzerling L.

Br J Cancer. 2018 Mar 20;118(6):785-792. doi: 10.1038/bjc.2017.489. Epub 2018 Feb 13.

PMID:
29438368
18.

A web platform for the network analysis of high-throughput data in melanoma and its use to investigate mechanisms of resistance to anti-PD1 immunotherapy.

Dreyer FS, Cantone M, Eberhardt M, Jaitly T, Walter L, Wittmann J, Gupta SK, Khan FM, Wolkenhauer O, Pützer BM, Jäck HM, Heinzerling L, Vera J.

Biochim Biophys Acta Mol Basis Dis. 2018 Jun;1864(6 Pt B):2315-2328. doi: 10.1016/j.bbadis.2018.01.020. Epub 2018 Feb 23.

PMID:
29410200
19.

BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy.

Dörrie J, Babalija L, Hoyer S, Gerer KF, Schuler G, Heinzerling L, Schaft N.

Int J Mol Sci. 2018 Jan 18;19(1). pii: E289. doi: 10.3390/ijms19010289.

20.

Concealed complete response in melanoma patients under therapy with immune checkpoint inhibitors: two case reports.

Schliep S, Agaimy A, Cavallaro A, Kiesewetter F, Schuler G, Heinzerling L.

J Immunother Cancer. 2018 Jan 15;6(1):2. doi: 10.1186/s40425-017-0309-3.

21.

Das Interesse an Solarien und Sonnenschutz im deutschsprachigen Raum.

Kirchberger MC, Kirchberger LF, Eigentler TK, Reinhard R, Berking C, Schuler G, Heinzerling L, Heppt MV.

J Dtsch Dermatol Ges. 2017 Dec;15(12):1192-1198. doi: 10.1111/ddg.13380_g. No abstract available.

PMID:
29228492
22.

Can checkpoint inhibitor therapy improve response to chemotherapy?

Kirchberger MC, Schilling B, Haferkamp S, Bosserhoff A, Schuler G, Heinzerling L.

J Cancer Res Clin Oncol. 2018 Jan;144(1):183-185. doi: 10.1007/s00432-017-2546-8. Epub 2017 Nov 24. No abstract available.

PMID:
29177557
23.

Interest in tanning beds and sunscreen in German-speaking countries.

Kirchberger MC, Kirchberger LF, Eigentler TK, Reinhard R, Berking C, Schuler G, Heinzerling L, Heppt MV.

J Dtsch Dermatol Ges. 2017 Dec;15(12):1192-1198. doi: 10.1111/ddg.13380. Epub 2017 Nov 17.

PMID:
29148618
24.

Life-threatening Autoimmune Cardiomyopathy Reproducibly Induced in a Patient by Checkpoint Inhibitor Therapy.

Tajmir-Riahi A, Bergmann T, Schmid M, Agaimy A, Schuler G, Heinzerling L.

J Immunother. 2018 Jan;41(1):35-38. doi: 10.1097/CJI.0000000000000190.

PMID:
29077601
25.

Clinical characteristics and outcome of 60 pediatric patients with malignant melanoma registered with the German Pediatric Rare Tumor Registry (STEP).

Offenmueller S, Leiter U, Bernbeck B, Garbe C, Eigentler T, Borkhardt A, Friedrich Classen C, Corbacioglu S, Dirksen U, Ebetsberger-Dachs G, Heinzerling L, Jorch N, Kuhlen M, Lawlor J, Niggli F, Streiter M, Schneider DT, Brecht I.

Klin Padiatr. 2017 Nov;229(6):322-328. doi: 10.1055/s-0043-118662. Epub 2017 Oct 10.

PMID:
29017184
26.

Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein.

Buschow SI, Ramazzotti M, Reinieren-Beeren IMJ, Heinzerling LM, Westdorp H, Stefanini I, Beltrame L, Hato SV, Ellebaek E, Gross S, Nguyen VA, Weinlich G, Ragoussis J, Baban D, Schuler-Thurner B, Svane IM, Romani N, Austyn JM, De Vries IJM, Schuler G, Cavalieri D, Figdor CG.

Oncotarget. 2017 Jun 27;8(40):67439-67456. doi: 10.18632/oncotarget.18698. eCollection 2017 Sep 15.

27.

Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.

Heppt MV, Heinzerling L, Kähler KC, Forschner A, Kirchberger MC, Loquai C, Meissner M, Meier F, Terheyden P, Schell B, Herbst R, Göppner D, Kiecker F, Rafei-Shamsabadi D, Haferkamp S, Huber MA, Utikal J, Ziemer M, Bumeder I, Pfeiffer C, Schäd SG, Schmid-Tannwald C, Tietze JK, Eigentler TK, Berking C.

Eur J Cancer. 2017 Sep;82:56-65. doi: 10.1016/j.ejca.2017.05.038. Epub 2017 Jun 22.

PMID:
28648699
28.

Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab.

Brüggemann C, Kirchberger MC, Goldinger SM, Weide B, Konrad A, Erdmann M, Schadendorf D, Croner RS, Krähenbühl L, Kähler KC, Hafner C, Leisgang W, Kiesewetter F, Dummer R, Schuler G, Stürzl M, Heinzerling L.

J Cancer Res Clin Oncol. 2017 Oct;143(10):1977-1984. doi: 10.1007/s00432-017-2450-2. Epub 2017 Jun 14.

PMID:
28616701
29.

Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma.

Heppt MV, Roesch A, Weide B, Gutzmer R, Meier F, Loquai C, Kähler KC, Gesierich A, Meissner M, von Bubnoff D, Göppner D, Schlaak M, Pföhler C, Utikal J, Heinzerling L, Cosgarea I, Engel J, Eckel R, Martens A, Mirlach L, Satzger I, Schubert-Fritschle G, Tietze JK, Berking C.

Eur J Cancer. 2017 Aug;81:36-44. doi: 10.1016/j.ejca.2017.05.014. Epub 2017 Jun 7.

PMID:
28600969
30.

Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions.

Hassel JC, Heinzerling L, Aberle J, Bähr O, Eigentler TK, Grimm MO, Grünwald V, Leipe J, Reinmuth N, Tietze JK, Trojan J, Zimmer L, Gutzmer R.

Cancer Treat Rev. 2017 Jun;57:36-49. doi: 10.1016/j.ctrv.2017.05.003. Epub 2017 May 18. Review.

PMID:
28550712
31.

Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients.

Gross S, Erdmann M, Haendle I, Voland S, Berger T, Schultz E, Strasser E, Dankerl P, Janka R, Schliep S, Heinzerling L, Sotlar K, Coulie P, Schuler G, Schuler-Thurner B.

JCI Insight. 2017 Apr 20;2(8). pii: 91438. doi: 10.1172/jci.insight.91438. [Epub ahead of print]

32.

Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.

Zimmer L, Apuri S, Eroglu Z, Kottschade LA, Forschner A, Gutzmer R, Schlaak M, Heinzerling L, Krackhardt AM, Loquai C, Markovic SN, Joseph RW, Markey K, Utikal JS, Weishaupt C, Goldinger SM, Sondak VK, Zager JS, Schadendorf D, Khushalani NI.

Eur J Cancer. 2017 Apr;75:47-55. doi: 10.1016/j.ejca.2017.01.009. Epub 2017 Feb 17.

PMID:
28214657
33.

Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity.

Gutzmer R, Koop A, Meier F, Hassel JC, Terheyden P, Zimmer L, Heinzerling L, Ugurel S, Pföhler C, Gesierich A, Livingstone E, Satzger I, Kähler KC; German Dermatooncology Group (DeCOG).

Eur J Cancer. 2017 Apr;75:24-32. doi: 10.1016/j.ejca.2016.12.038. Epub 2017 Feb 16.

PMID:
28214654
34.

Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy.

Moreira A, Leisgang W, Schuler G, Heinzerling L.

Immunotherapy. 2017 Jan;9(2):115-121. doi: 10.2217/imt-2016-0138.

PMID:
28128709
35.

A review of serious adverse effects under treatment with checkpoint inhibitors.

Heinzerling L, Goldinger SM.

Curr Opin Oncol. 2017 Mar;29(2):136-144. doi: 10.1097/CCO.0000000000000358. Review.

PMID:
28059853
36.

The tanning habits and interest in sunscreen of Google users: what happened in 12 years?

Kirchberger MC, Heppt MV, Eigentler TK, Kirchberger MA, Schuler G, Heinzerling L.

Photodermatol Photoimmunol Photomed. 2017 Mar;33(2):68-74. doi: 10.1111/phpp.12289. Epub 2017 Jan 19.

PMID:
28039945
37.

Tumour stage distribution and survival of malignant melanoma in Germany 2002-2011.

Schoffer O, Schülein S, Arand G, Arnholdt H, Baaske D, Bargou RC, Becker N, Beckmann MW, Bodack Y, Böhme B, Bozkurt T, Breitsprecher R, Buchali A, Burger E, Burger U, Dommisch K, Elsner G, Fernschild K, Flintzer U, Funke U, Gerken M, Göbel H, Grobe N, Gumpp V, Heinzerling L, Kempfer LR, Kiani A, Klinkhammer-Schalke M, Klöcking S, Kreibich U, Knabner K, Kuhn P, Lutze S, Mäder U, Maisel T, Maschke J, Middeke M, Neubauer A, Niedostatek A, Opazo-Saez A, Peters C, Schell B, Schenkirsch G, Schmalenberg H, Schmidt P, Schneider C, Schubotz B, Seide A, Strecker P, Taubenheim S, Wackes M, Weiß S, Welke C, Werner C, Wittekind C, Wulff J, Zettl H, Klug SJ.

BMC Cancer. 2016 Dec 5;16(1):936.

38.

The neurotrophin Neuritin1 (cpg15) is involved in melanoma migration, attachment independent growth, and vascular mimicry.

Bosserhoff AK, Schneider N, Ellmann L, Heinzerling L, Kuphal S.

Oncotarget. 2017 Jan 3;8(1):1117-1131. doi: 10.18632/oncotarget.13585.

39.

Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG "GERMELATOX survey") versus melanoma recurrence to quantify patients' relative values for adjuvant therapy.

Kaehler KC, Blome C, Forschner A, Gutzmer R, Haalck T, Heinzerling L, Kornek T, Livingstone E, Loquai C, Maul LV, Lang BM, Schadendorf D, Stade B, Terheyden P, Utikal J, Wagner T, Hauschild A, Garbe C, Augustin M.

Medicine (Baltimore). 2016 Nov;95(46):e5375.

40.

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab.

Weide B, Martens A, Hassel JC, Berking C, Postow MA, Bisschop K, Simeone E, Mangana J, Schilling B, Di Giacomo AM, Brenner N, Kähler K, Heinzerling L, Gutzmer R, Bender A, Gebhardt C, Romano E, Meier F, Martus P, Maio M, Blank C, Schadendorf D, Dummer R, Ascierto PA, Hospers G, Garbe C, Wolchok JD.

Clin Cancer Res. 2016 Nov 15;22(22):5487-5496. doi: 10.1158/1078-0432.CCR-16-0127. Epub 2016 May 16.

41.

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy.

Heinzerling L, Ott PA, Hodi FS, Husain AN, Tajmir-Riahi A, Tawbi H, Pauschinger M, Gajewski TF, Lipson EJ, Luke JJ.

J Immunother Cancer. 2016 Aug 16;4:50. doi: 10.1186/s40425-016-0152-y. eCollection 2016.

42.

Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma.

Kirchberger MC, Hauschild A, Schuler G, Heinzerling L.

Eur J Cancer. 2016 Sep;65:182-4. doi: 10.1016/j.ejca.2016.07.003. Epub 2016 Aug 6.

PMID:
27501507
43.

Anti-TNF-refractory colitis after checkpoint inhibitor therapy: Possible role of CMV-mediated immunopathogenesis.

Lankes K, Hundorfean G, Harrer T, Pommer AJ, Agaimy A, Angelovska I, Tajmir-Riahi A, Göhl J, Schuler G, Neurath MF, Hohenberger W, Heinzerling L.

Oncoimmunology. 2016 Feb 18;5(6):e1128611. doi: 10.1080/2162402X.2015.1128611. eCollection 2016 Jun.

44.

Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma.

Kähler KC, Hassel JC, Heinzerling L, Loquai C, Mössner R, Ugurel S, Zimmer L, Gutzmer R; “Cutaneous Side Effects” Committee of the Work Group Dermatological Oncology (ADO).

J Dtsch Dermatol Ges. 2016 Jul;14(7):662-81. doi: 10.1111/ddg.13047.

PMID:
27373241
45.

Nebenwirkungsmanagement bei Immun-Checkpoint-Blockade durch CTLA-4- und PD1-Antikörper beim metastasierten Melanom.

Kähler KC, Hassel JC, Heinzerling L, Loquai C, Mössner R, Ugurel S, Zimmer L, Gutzmer R; für das Komitee „Kutane Nebenwirkungen“ der Arbeitsgemeinschaft Dermatologische Onkologie (ADO).

J Dtsch Dermatol Ges. 2016 Jul;14(7):662-83. doi: 10.1111/ddg.13047_g. No abstract available.

PMID:
27373240
46.

Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial.

Eigentler TK, Gutzmer R, Hauschild A, Heinzerling L, Schadendorf D, Nashan D, Hölzle E, Kiecker F, Becker J, Sunderkötter C, Moll I, Richtig E, Pönitzsch I, Pehamberger H, Kaufmann R, Pföhler C, Vogt T, Berking C, Praxmarer M, Garbe C; Dermatologic Cooperative Oncology Group (DeCOG).

Ann Oncol. 2016 Aug;27(8):1625-32. doi: 10.1093/annonc/mdw225. Epub 2016 Jun 10.

PMID:
27287206
47.

Which melanoma patient carries a BRAF-mutation? A comparison of predictive models.

Eigentler T, Assi Z, Hassel JC, Heinzerling L, Starz H, Berneburg M, Bauer J, Garbe C.

Oncotarget. 2016 Jun 14;7(24):36130-36137. doi: 10.18632/oncotarget.9143.

48.

Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy.

Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, Schmidgen MI, Gutzmer R, Utikal JS, Göppner D, Hassel JC, Meier F, Tietze JK, Thomas I, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling LM.

Eur J Cancer. 2016 Jun;60:190-209. doi: 10.1016/j.ejca.2016.02.025. Epub 2016 Apr 13.

PMID:
27085692
49.

Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy.

Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I, Schmidgen MI, Gutzmer R, Utikal JS, Göppner D, Hassel JC, Meier F, Tietze JK, Forschner A, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling LM.

Eur J Cancer. 2016 Jun;60:210-25. doi: 10.1016/j.ejca.2016.02.024. Epub 2016 Apr 13.

PMID:
27084345
50.

The Varieties and Limits of Transparency in U.S. Food Law.

Heinzerling L.

Food Drug Law J. 2015;70(1):11-24. No abstract available.

PMID:
26292469

Supplemental Content

Loading ...
Support Center